Mobocertinib: First Approval

Mobocertinib (EXKIVITY (TM)) is a first-in-class EGFR tyrosine kinase inhibitor being developed for the treatment of EGFR exon 20 insertion (EGFRex20ins) -positive non-small cell lung cancer (NSCLC). Based on efficacy in patients whose disease had progressed on or after platinum-based therapy in a phase I/II trial, mobocertinib was recently granted accelerated approval in the USA in this indication. The drug is also being assessed for marketing approval in various other countries and territories including the EU and China. This article summarizes the milestones in the development of mobocertinib leading to this first approval in the USA for locally advanced or metastatic EGFRex20ins-positive NSCLC that has progressed on or after platinum-based chemotherapy.

Automated summary

Mobocertinib, a first-in-class EGFR tyrosine kinase inhibitor, has been granted accelerated approval in the USA for the treatment of EGFRex20ins-positive NSCLC. The drug is currently under assessment for marketing approval in various countries and territories. This article summarizes the milestones in the development of mobocertinib leading to its first approval in the USA.